Last updated: February 20, 2026
What is NDC 39822-6250?
NDC 39822-6250 corresponds to Gvoke Glucagon, a prescription medication used for the treatment of severe hypoglycemia in diabetic patients. Originated by Xeris Pharmaceuticals, Gvoke is a ready-to-use, pre-filled autoinjector designed for emergency administration.
Market Size and Competitors
Current Market Scope
- Diabetes prevalence: Approximately 37.3 million Americans, with Type 1 and Type 2 diabetes comprising the majority.
- Severe hypoglycemia interventions:
- Traditional options: Glucagon kits (e.g., GlucaGen, Baqsimi).
- Alternative forms: Nasal sprays (Baqsimi), auto-injectors (Gvoke).
- Diagnosed cases eligible for Gvoke: Estimated at 4-5 million, with usage driven primarily by emergency preparedness in high-risk patients.
Key Competitors
| Product |
Formulation |
Market Share (2022) |
Launch Year |
Price Range (per dose) |
| GlucaGen |
Powder for reconstitution |
45% |
1991 |
$285 (reconstituted) |
| Baqsimi (nasal) |
Powder nasal spray |
35% |
2019 |
$325 (per spray) |
| Gvoke |
Autoinjector |
15% |
2019 |
$325 (per prefilled syringe) |
Market shares are estimates based on pharmacy data and sales figures.
Price Projections (Next 3-5 Years)
Factors Influencing Price
- Manufacturing costs: Autoinjector technology reduces handling costs.
- Market competition: Introduction of biosimilars or generics could pressure pricing downward.
- Insurance dynamics: Reimbursement policies influence consumer out-of-pocket costs.
- Regulatory changes: Price controls or new patent approvals.
Current Pricing Trends
- Gvoke's current list price is approximately $325 per prefilled autoinjector.
- Pharmacy retail prices are typically 20-30% lower due to insurance discounts.
- Historically, prices for glucagon formulations increased by approximately 3-5% annually over the past five years.
Future Price Outlook
| Year |
Estimated Price Range |
Key Drivers |
| 2023 |
$310 - $340 |
Stable demand, no significant competition |
| 2024 |
$305 - $340 |
Introduction of biosimilars, insurance negotiations |
| 2025 |
$300 - $330 |
Increased market penetration, generic entries anticipated |
| 2026 |
$295 - $325 |
Competition stabilizes prices, demand growth |
Potential Price Decline Scenario
If biosimilar glucagon products enter the market, prices could decrease by 15-20% over three years, aligning closer to $250 per dose.
Regulatory and Market Entry Considerations
- Patent status:
- Original patent expired, open for biosimilar development.
- Gvoke operates under an orange book expiry in 2028-2029.
- Reimbursement:
- Medicare Part D and commercial plans predominantly cover Gvoke.
- Value-based contracts may influence future discounts.
- Healthcare adoption:
- Increased awareness of emergency glucagon options drives higher utilization.
- Manufacturers focus on extending indications, including pediatric and non-diabetic emergencies.
Key Takeaways
- Gvoke faces limited direct competition but must contend with nasal formulations and traditional glucagon kits.
- Price stability is likely through 2024, with possible declines if biosimilars gain approval.
- Rising demand for user-friendly emergency glucagon formulations supports sustained revenue.
- Market entry barriers for biosimilars are manageable, with patent expiries approaching.
- Reimbursement trends and insurance policies heavily influence consumer pricing.
FAQs
1. What factors could accelerate price reductions for Gvoke?
Entry of biosimilars, decreased manufacturing costs, and wider insurance negotiations could lower prices.
2. How does Gvoke compare with nasal formulations in pricing and ease of use?
Gvoke is priced similarly to nasal sprays but offers a pre-filled autoinjector for patients preferring injectable forms. Nasal sprays may have lower administration barriers but are often more expensive on a per-dose basis.
3. What is the expected market growth for emergency glucagon drugs?
Projected compound annual growth rate (CAGR) is approximately 5-7% over the next five years due to rising diabetes prevalence and awareness.
4. How will patent expirations impact Gvoke’s market?
Patent expiry around 2028-2029 may lead to biosimilar competition, exerting downward pressure on pricing.
5. Are there emerging therapies that could disrupt the glucagon market?
Research into long-acting glucagon analogs and alternative hypoglycemia treatments could influence future market dynamics, but none are currently close to widespread adoption.
References
- Centers for Disease Control and Prevention (CDC). (2022). National Diabetes Statistics Report.
- IQVIA. (2022). Pharmacy Market Data.
- U.S. Food and Drug Administration (FDA). (2022). Orange Book.
- Xeris Pharmaceuticals. (2022). Gvoke Product Information.
- MarketWatch. (2022). Forecasts for Emergency Glucagon Market.
[1] Centers for Disease Control and Prevention. (2022). National Diabetes Statistics Report.
[2] IQVIA. (2022). Pharmacy Market Data.
[3] U.S. Food and Drug Administration. (2022). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
[4] Xeris Pharmaceuticals. (2022). Gvoke Product Information.
[5] MarketWatch. (2022). Forecasts for Emergency Glucagon Market.
